HighTide Therapeutics (“HighTide”) and Silexon Tech (“Silexon”) jointly announced a long-term strategic collaboration agreement in new drug research and development.
October 10, 2019
Learn More
Based on Safety Data Review, DMC Recommends Continuing Trial
September 02, 2019
Learn More
SHENZHEN, CHINA and ROCKVILLE, MD, July 11, 2019 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that it has become a resident company at JLABS @ Shanghai.
July 10, 2019
Learn More
SHENZHEN, CHINA and ROCKVILLE, MD, July 02, 2019 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that Adrian M. Di Bisceglie, M.D., has been appointed as Chief Medical Officer.
July 02, 2019
Learn More
HighTide Therapeutics is proud to sponsor the annual PSC patient advocacy conference organized by PSC Partners Seeking a Cure. This year the annual conference will take place June 21-23 in Rochester, Minnesota in partnership with Mayo Clini
June 04, 2019
Learn More
Liping Liu, founder, CEO & CSO of HighTide Therapeutics invited to present at the HKEX Biotech Week 2019 conference, 28-30 May in Hong Kong. Dr. Liu presented HighTide Therapeutics in the “Deep Dive Workshop” on Day 3.
June 02, 2019
Learn More
We will contact you as soon as possible
© 2024 HighTide Therapeutics, Inc.